GlassScriptPhysician profile
Taylor Thrash
NPI 1871158121
$3,932.34
in general payments reported to CMS, 2019-2025
40 companies · $902 in 2025
The $902 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.62 · 2022: $563 · 2023: $1,138 · 2024: $1,310 · 2025: $902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,334 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,334.10 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $723.98 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $485.53 | 2022-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $249.09 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $204.76 | 2023-2025 | Farxiga, Airsupra, Lokelma |
| Amgen INC. | $197.73 | 2022-2025 | Repatha, Otezla, Prolia |
| Abbott Laboratories | $168.38 | 2023-2025 | Freestyle Libre, Freestyle Libre 3 |
| Alkermes, INC. | $159.45 | 2023-2025 | Vivitrol, Vivitrol |
| Lilly USA, LLC | $147.35 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Xeris Pharmaceuticals, INC. | $145.25 | 2023-2024 | Gvoke Hypopen |
| Pfizer INC. | $134.41 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $118.65 | 2022-2024 | Verquvo, Belsomra, Gardasil 9 |
| Sanofi-Aventis U.S. LLC | $96.46 | 2024 | |
| Dexcom, INC. | $95.07 | 2023 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $90.16 | 2024 | Korlym |
| Exact Sciences Corporation | $87.43 | 2023-2025 | Cologuard Collection Kit |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Thrash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.